Lexaria Bioscience/$LEXX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lexaria Bioscience
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Ticker
$LEXX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Kelowna, Canada
Employees
7
ISIN
US52886N4060
Website
LEXX Metrics
BasicAdvanced
$19M
-
-$0.59
0.85
-
Price and volume
Market cap
$19M
Beta
0.85
52-week high
$1.90
52-week low
$0.92
Average daily volume
119K
Financial strength
Current ratio
4.239
Quick ratio
3.772
Long term debt to equity
1.396
Total debt to equity
1.83
Profitability
EBITDA (TTM)
-9.263
Gross margin (TTM)
99.48%
Net profit margin (TTM)
-1,784.18%
Operating margin (TTM)
-1,774.08%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-77.60%
Return on equity (TTM)
-145.55%
Valuation
Price to revenue (TTM)
30.293
Price to book
2.46
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
-2.113
Free cash flow yield (TTM)
-47.32%
Free cash flow per share (TTM)
-47.32%
Growth
Revenue change (TTM)
29.95%
Earnings per share change (TTM)
-6.62%
3-year revenue growth (CAGR)
23.44%
10-year revenue growth (CAGR)
68.31%
3-year earnings per share growth (CAGR)
-23.03%
10-year earnings per share growth (CAGR)
-17.29%
LEXX News
AllArticlesVideos
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
TheNewswire·1 week ago
Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule
Accesswire·1 week ago
Lexaria Attending BIO International Convention
TheNewswire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lexaria Bioscience stock?
Lexaria Bioscience (LEXX) has a market cap of $19M as of June 20, 2025.
What is the P/E ratio for Lexaria Bioscience stock?
The price to earnings (P/E) ratio for Lexaria Bioscience (LEXX) stock is 0 as of June 20, 2025.
Does Lexaria Bioscience stock pay dividends?
No, Lexaria Bioscience (LEXX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Lexaria Bioscience dividend payment date?
Lexaria Bioscience (LEXX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lexaria Bioscience?
Lexaria Bioscience (LEXX) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.